Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Chrome Holding Co. reported the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023 results: revenue $61 million, net income $105 million (Net loss). Guidance raised.
- Period
- the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023
- Revenue
- $61 million
- Net income
- $105 million (Net loss)
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Total revenue for the three months ended June 30, 2023, was $61 million, compared to $65 million for the same period in the prior year, representing a decrease of 6%.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Kenneth Hillan retired as Chief Therapeutics Officer at Chrome Holding Co..
- Action
- retired
- Role
- Chief Therapeutics Officer
Exact text from the filing
On August 2, 2023 (the “Notice Date”), Dr. Kenneth Hillan, Chief Therapeutics Officer of 23andMe Holding Co. (the “Company”), notified the Company of his decision to retire (the “Retirement”).
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Chrome Holding Co. announced a restructuring with charges of approximately $3 million affecting Therapeutics segment (approximately 71 employees).
- Type
- restructuring
- Charge
- approximately $3 million
- Affected area
- Therapeutics segment
- Headcount
- approximately 71 employees
Exact text from the filing
modification of certain stock options and restricted stock units (“equity compensation charges”). Severance and benefit continuation charges are estimated to be approximately $3 million and are expected to be recognized primarily in the second quarter of fiscal 2024, with the majority of such charges anticipated to be paid in cash during the same quarter. Equity
View on SEC.gov